ベンゾジアゼピン作用は,特定のガンマ-アミノバター酸 ((A) 受容体亜型によって媒介されます
U Rudolph1, F Crestani, D Benke
1Institute of Pharmacology, University of Zürich, Switzerland. rudolph@pharma.unizh.ch
Nature
|November 5, 1999
まとめ
ベンゾジアゼピン薬は,特定のガンマ-アミノバター酸A型 (GABA(A)) 受容体を標的とする. この研究では,アルファ1-サブユニット変異がダイアゼパムを阻害することを示しています.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- GABA (A) 受容体は,警戒心や不安などの脳機能を調節するために不可欠です.
- ベンゾジアゼピンは,GABA (((A)) 受容体を調節する薬として広く使用されています.
- 特定のGABA (A) 受容体のサブタイプは,異なる脳領域で発現します.
研究 の 目的:
- ベンゾジアゼピン効果を媒介するアルファ1-サブユニットGABA(A) 受容体の役割を調査する.
- 特定のベンゾジアゼピン誘発行動に責任を持つGABA (A) 受容体のサブタイプを決定する.
主な方法:
- アルファ1〜GABA〜A受容体のベンゾジアゼピン感受性が変化したアルファ1〜H101R) 変異マウスを生成した.
- 変異性や野生型のマウスにダイアゼパムを投与した.
- 鎮静,不安,記憶喪失,運動調整などの様々な行動反応を評価した.
主要な成果:
- アルファ1-GABA(A) 受容体は,ディアゼパムの鎮静作用と記憶喪失作用に不可欠である.
- ベンゾジアゼピン誘発の抗不安薬,筋肉リラックス剤,運動障害効果は,他のGABA (A) 受容体亜型によって媒介されます.
- ディアゼパムによるエタノール強化は,アルファ1-GABA(A) 受容体とも関係ありません.
結論:
- ベンゾジアゼピン作用は,異なる神経回路の特定のGABA (A) 受容体サブタイプによって媒介されます.
- この発見は,GABA (A) 受容体を標的とする新薬の合理的な設計にとって重要である.
- サブタイプ特有の機能を理解することで,より選択的な治療薬の開発が可能になります.
関連する概念動画
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...


